Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

141.

Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing.

Proc. Natl. Acad. Sci. U.S.A.
Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T, Jiang D, Gaultier C, Guerin F, Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB.
| Dec 17, 2013
142.

NFATc1 and NFATc2 repress spontaneous osteoarthritis.

Proc. Natl. Acad. Sci. U.S.A.
Greenblatt MB, Ritter SY, Wright J, Tsang K, Hu D, Glimcher LH, Aliprantis AO.
| Dec 3, 2013
143.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

JAMA.
Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, Hennekens C.
| Jan 15, 2014
144.

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

JAMA.
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM, AbouEzzeddine O.
| Dec 18, 2013
145.

Stenting and medical therapy for atherosclerotic renal-artery stenosis.

N. Engl. J. Med.
Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB, Dworkin LD, Dworkin L.
| Jan 2, 2014
146.

Mitral-valve repair versus replacement for severe ischemic mitral regurgitation.

N. Engl. J. Med.
Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, Smith PK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M, Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL, Miller MA, Woo YJ, D'Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ, O'Gara PT, Michler RE, Kron IL, Miller MA.
| Jan 2, 2014
147.

The cardiovascular disease researcher.

JAMA.
Gaziano JM, Peterson E.
| Nov 20, 2013
148.

The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia type and laterality.

Nature.
Boskovski MT, Yuan S, Pedersen NB, Goth CK, Makova S, Clausen H, Brueckner M, Khokha MK.
| Dec 19, 2013
149.

Abatacept in B7-1-positive proteinuric kidney disease.

N. Engl. J. Med.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P.
| Dec 19, 2013
150.

The quest to overcome resistance to EGFR-targeted therapies in cancer.

Nat. Med.
Chong CR, Jänne PA.
| 11 07, 2013
151.

Clinical problem-solving. A curious case of chest pain.

N. Engl. J. Med.
Liao JM, Stewart GC, Padera RF, Miller AL, Loscalzo J.
| Nov 7, 2013
152.

Surgeons, sleep, and patient safety.

JAMA.
Zinner MJ, Fresichlag JA.
| Nov 6, 2013
153.

Application of user-guided automated cytometric data analysis to large-scale immunoprofiling of invariant natural killer T cells.

Proc. Natl. Acad. Sci. U.S.A.
Hu X, Kim H, Brennan PJ, Han B, Baecher-Allan CM, De Jager PL, Brenner MB, Raychaudhuri S.
| Nov 19, 2013
154.

The merits of subtyping obesity: one size does not fit all.

JAMA.
Field AE, Camargo CA, Ogino S.
| Nov 27, 2013
155.

Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.

Cell.
Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, Elledge SJ.
| Nov 7, 2013
156.

Cancer-drug discovery and cardiovascular surveillance.

N. Engl. J. Med.
Groarke JD, Cheng S, Moslehi J.
| Nov 7, 2013
157.

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

JAMA.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela EL, Perin MA, Devito FS, Labrunie A, Salvadori D, Gusmão M, Staico R, Costa JR, de Castro JP, Abizaid AS, Bhatt DL, Feres F.
| Dec 18, 2013
158.

Improving patient safety through transparency.

N. Engl. J. Med.
Kachalia A.
| Oct 31, 2013
159.

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

Proc. Natl. Acad. Sci. U.S.A.
Xu X, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, Shi J, Wu J, Kantoff PW, Lippard SJ, Langer R, Walker GC, Farokhzad OC.
| Nov 12, 2013
160.

Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2.

Proc. Natl. Acad. Sci. U.S.A.
Portal D, Zhou H, Zhao B, Kharchenko PV, Lowry E, Wong L, Quackenbush J, Holloway D, Jiang S, Lu Y, Kieff E.
| Nov 12, 2013